CLU
0.015
150%
HYT
0.006
-57.1%
WNX
0.115
105.4%
TKM
0.058
-47.3%
ITM
0.053
71%
LML
0.007
-46.2%
AU1
0.034
54.5%
LKO
0.265
-37.6%
MRQ
0.003
50%
ATC
0.002
-33.3%
QEM
0.022
46.7%
OVT
0.002
-33.3%
AQZ
0.83
41.9%
TMX
0.002
-33.3%
ALB
0.056
40%
ARO
0.003
-25%
NFM
0.007
40%
NES
0.003
-25%
SLD
0.6
39.5%
ALU
0.67
-23.9%
SNT
0.035
34.6%
BTN
0.012
-20%
ABE
0.02
33.3%
ENL
0.004
-20%
HIQ
0.008
33.3%
FIN
0.004
-20%
MHM
0.16
33.3%
MAY
0.004
-20%
SMM
0.012
33.3%
PCL
0.008
-20%
WC1
0.016
33.3%
IBR
0.056
-18.8%
FAL
0.55
32.5%
BPG
0.295
-18.1%
MYE
0.53
32.5%
AGE
0.044
-17%
PPK
0.45
32.4%
CD2
0.3
-16.7%
AHK
0.315
31.3%
ZEU
0.005
-16.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Short Video: Tryptamine Therapeutics (ASX:TYP): Clinical-stage biotech focused on psychedelic drug development

Tryptamine Therapeutics Limited (ASX:TYP) is a clinical-stage biotech and its current primary focus is the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs. Tryptamine Therapeutics CEO and Executive Director Jason Carroll speaks with The Stock Network’s Lel Smits.

🧬 Phase 2a clinical trial now underway – investigating the treatment of Irritable Bowel Syndrome, or IBS
🏥 Recently dosed the first patient at Massachusetts General Hospital, U.S.A
🍄 First time this prestigious hospital has administered psilocybin in a clinical setting
‍
Watch the full interview ⚡ https://youtu.be/iug95UNKcMs